Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accounts Payables (2016 - 2025)

Vanda Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $68.3 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 74.74% to $68.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $68.3 million, a 74.74% increase, with the full-year FY2025 number at $68.3 million, up 74.74% from a year prior.
  • Accounts Payables hit $68.3 million in Q4 2025 for Vanda Pharmaceuticals, up from $47.6 million in the prior quarter.
  • Over the last five years, Accounts Payables for VNDA hit a ceiling of $68.3 million in Q4 2025 and a floor of $26.1 million in Q1 2021.
  • Historically, Accounts Payables has averaged $41.7 million across 5 years, with a median of $39.2 million in 2024.
  • Biggest five-year swings in Accounts Payables: soared 96.87% in 2022 and later tumbled 36.44% in 2023.
  • Tracing VNDA's Accounts Payables over 5 years: stood at $34.4 million in 2021, then soared by 32.27% to $45.6 million in 2022, then fell by 15.57% to $38.5 million in 2023, then rose by 1.63% to $39.1 million in 2024, then surged by 74.74% to $68.3 million in 2025.
  • Business Quant data shows Accounts Payables for VNDA at $68.3 million in Q4 2025, $47.6 million in Q3 2025, and $57.1 million in Q2 2025.